2021-09-28 16:25:22 Pfizer and BioNTech Submit Covid Vaccine Data for Kids 5-11

Pfizer and BioNTech Submit Covid Vaccine Data for Kids 5-11

On Tuesday, Pfizer and BioNTech announced that they had submitted data to the Food and Drug Administration demonstrating that their coronavirus vaccine is safe and effective in children aged 5 to 11.

The companies stated that they would submit a formal request to regulators in the coming weeks to allow a pediatric dose of their vaccine to be administered in the United States. Similar requests will be made to European regulators as well as those in other countries.

Just over a week ago, Pfizer and BioNTech announced positive results from a clinical trial with over 2,200 participants in that age group. The FDA has stated that the data will be analyzed as soon as possible.

Last week, the companies announced that their vaccine had been shown to be safe and effective in low doses in children aged 5 to 11, giving parents in the United States hope that a return to in-person schooling has put their children at risk of infection.

In the United States, approximately 28 million children aged 5 to 11 would be eligible for the vaccine, far more than the 17 million aged 12 to 15 who became eligible in May.

However, it is unclear how many of the younger generation will be immunized. Inoculations among older children have lagged: according to federal data, only about 42 percent of children aged 12 to 15 have been fully vaccinated in the United States, compared to 66 percent of adults.

Although many parents are still eager to immunize their children, polls show that some parents have reservations. According to a Kaiser Family Foundation survey published last month, 26 percent of parents of children ages 5 to 11 would vaccinate their children “right away” once doses were authorized for their age group, 40 percent would “wait and see” how the vaccine worked before doing so, and 25 percent would not have their child vaccinated at all.

Unvaccinated children who contract the coronavirus are less likely to become seriously ill, leading some parents to question whether the risks of a new vaccine outweigh the benefits.

Furthermore, some vaccinated parents have expressed concerns about the relatively small size of children’s trials as well as a lack of data on the long-term safety of the shots.

Source link

Other News

Subscribe to our World NEWS Letter

Pfizer and BioNTech Submit Covid Vaccine Data for Kids 5-11